全球的肝臟疾病治療藥市場 是由出版商BCC Research在2012年01月所出版的。
這份英文市場調查報告書包含187 Pages 價格從美金4850起跳。
本報告書內容包括:全球的肝臟疾病治療藥市場的現況與展望的調查分析、肝臟疾病的種類與概要、治療所治療的主要藥劑的種類及概要、全球的主要地區之肝臟疾病的罹患率、藥劑種類・疾病區分・地區分類的市場規模實績・預測（∼2016年）、法律規範環境・藥劑開發趨勢等市場影響因素的分析、主要製造業者・供給業者的市場佔有率、主要企業的介紹等彙整、內容綱要摘記如下:
第1章 介紹
第2章 實施摘要
第3章 概要
- 定義
- 肝臟
- 肝臟的動態
- 肝臟疾病的般性症狀
- 肝臟疾病
第4章 治療的分類：疾病・產品區分分類
- 病毒性肝疾病・肝炎
- 肝腫瘤・肝臟癌
- 先天性肝障礙
- 自我免疫性肝障礙
- 酒精性肝臟疾病
- 慢性肝臟疾病
- 非酒精性脂肪肝
第5章 法律規範環境
第6章 罹患率
第7章 產業結構
- 肝臟疾病治療所使用的醫藥品：主要企業的市場佔有率
- 化學療法
第8章 新的開發趨勢
第9章 市場分析：藥劑種類分類
- 市場收益
- 市場佔有率
- 疫苗
- 抗病毒藥
- 免疫球蛋白
- 化學療法
- 標的治療
- 威爾森病的治療所使用的藥劑
- 類固醇
- 免疫抑制劑
- 代謝拮抗劑
- 肌肉增強劑
- 酒精依存症的治療藥
- 抗拒絶藥劑
- 與感染病競爭的藥劑
- 抗真菌藥預防投藥
- 膽石溶解劑
- 非酒精性脂肪肝治療的其他醫藥品
- 市場佔有率：肝臟疾病治療所使用的醫藥品種類・地區分類
第10章 市場：各種疾病種類
- 肝炎
- 肝腫瘤
- 自我免疫疾病
- 酒精性肝臟疾病
- 慢性肝臟疾病
- 非酒精性脂肪肝
- 市場佔有率：各種疾病種類
第11章 藥劑誘發性肝臟疾病
第12章 專利分析
第13章 現在的狀況與未來的展望
第14章 企業介紹
第15章 附錄
圖表
Abstract
REPORT HIGHLIGHTS
- In 2009, the global market for drugs used to treat liver disease was worth
approximately $12.4 billion. Sales in 2010 decreased and the market did not
see much progress, causing overall global sales to remain stagnant at $12.4
billion. Estimated sales in 2011 a projected $12 billion (excluding protease
inhibitors). The market is expected to rise at a CAGR of 3.3% and reach
nearly $14.2 billion by 2016.
- The U.S. region constituted approximately 36% of the total market for
drugs used to treat liver disease in 2010 and was valued at $4.5 billion. In
2011, the market continued to decrease and will hit nearly $4.2 billion. BCC
expects this market to increase in the future rising at a CAGR of 3% to reach
nearly $4.9 billion by 2016.
- The European market constituted approximately 31% of the total market and
was $3.8 billion in 2010. This market is expected to see a decrease in 2011
totaling nearly $3.6 billion. This market is forecast to grow at a CAGR of 1%
and should be worth $3.7 billion by 2016.
SUMMARY FIGURE
GLOBAL REVENUE FOR DRUGS USED TO TREAT LIVER DISEASES BY REGION,
2009-2016 ($ MILLIONS)
Source: BCC Research
STUDY OBJECTIVES
BCC Research's goal in conducting this study is to provide an overview of the
current and future characteristics of the global market for liver disease
drugs, including the market for end users. The key objective is to present a
comprehensive analysis of the current liver disease drug market and its future
direction by utilizing new methods for preventing globally widespread disease.
This report explores present and future strategies within the liver disease
drug market, including market sizes, market leaders, market overview, and
various other market factors, as well as the market for end users. The
current state of the market, its setbacks, its innovations, and its future
needs are also discussed.
A detailed analysis of the liver disease drug market and the industry
structure has been conducted. This includes the different categories of liver
disease drugs and the various types of liver disease broken down by market
share belonging to leading manufacturers and/or suppliers. Revenues for each
drug category and disease type are broken down by region. Sales figures are
estimated for the 5-year period from 2011 through 2016.
The strategies and the prospects of the current market are also discussed.
Companies that manufacture and sell new and innovative liver disease-related
drugs are also profiled.
REASONS FOR DOING THIS STUDY
This study was conducted to provide detailed information regarding different
liver disease drugs in response to an increasing need for new and innovative
drug treatments. This industry is experiencing growth, as new product lines
have been launched (e.g., Protease inhibitors for the treatment of hepatitis).
The study looks at most of the different drug types and different liver
diseases. It cites the research and development for almost all new drugs and
applications. The changes in market behavior demonstrate the need to focus on
this segment. Additionally, the study discusses the treatment options
provided by these drugs to end users. Acquisitions, mergers, and alliances by
companies and global organizations are also discussed.
SCOPE OF THE STUDY
The scope of this study encompasses liver disease drug markets by various
types. BCC Research analyzes each market by category with its applications in
different regions of the world. It also analyzes the market leaders,
regulatory environment, technology, market projections, and market share.
Application issues include the latest trends and developments in each liver
disease drug category.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this
study. BCC conducted a comprehensive literature search, which included
technical newsletters and journals, as well as many other sources. Data were
collected through interviews and correspondence with various trade experts.
Projections were based on estimates such as the current number of end users,
potential end users, mergers and acquisitions, and market trends.
INFORMATION SOURCES
Many companies within the industry were surveyed to obtain market data,
including manufacturers, end users of drug delivery systems, members of the
pharmaceutical and biotechnical industries, and research institutes. Data
were gathered from various industry sources. BCC spoke with officials within
the industry and also consulted newsletters, company literature, product
literature, technical articles, journals, indexes, and abstracts. Exhaustive
investigations of databases by key terminology were completed. In addition,
data were compiled from current financial, trade, and government sources.
ABOUT THE AUTHOR
This study has been carried out by a team of professionals in the
biotechnology industry. The project manager is Shalini S. Dewan, who holds a
Master's degree in Pharmaceutical Chemistry and has more than 14 years of
industry experience.
Table of Contents
Liver Disease Treatments: The Global Market
Chapter - 1: INTRODUCTION - Complimentary
- STUDY OBJECTIVES
- REASONS FOR DOING THIS STUDY
- INTENDED AUDIENCE
- SCOPE OF THE STUDY
- METHODOLOGY
- INFORMATION SOURCES
- BCC ONLINE SERVICES
- ABOUT THE AUTHOR
- RELATED BCC RESEARCH REPORTS
- DISCLAIMER
Chapter - 2: EXECUTIVE SUMMARY
- Table 0: GLOBAL REVENUE FOR DRUGS USED TO TREAT LIVER DISEASES BY REGION,
THROUGH 2016
- Figure 0: GLOBAL REVENUE FOR DRUGS USED TO TREAT LIVER DISEASES BY REGION,
2009-2016
Chapter - 3: OVERVIEW
- DEFINITIONS
- LIVER
- FUNCTIONS OF LIVER
- COMMON SYMPTOMS OF LIVER DISEASE
- LIVER DISEASE
- Table 1: CLASSIFICATION OF LIVER DISEASE
Chapter - 4: CLASSIFICATION OF THERAPIES BY DISEASE AND PRODUCTS ON THE MARKET
- VIRUS-INDUCED LIVER DISEASE AND HEPATITIS
- LIVER TUMORS AND LIVER CANCER
- CONGENITAL LIVER DEFECTS
- AUTOIMMUNE LIVER DISORDERS
- ALCOHOL-INDUCED LIVER DISEASE
- CHRONIC LIVER DISEASE
- NON-ALCOHOLIC FATTY LIVER
Chapter - 5: REGULATORY ASPECTS
- Table 22: NEW DRUG APPROVALS, 2008 - AUGUST 2011
- Table 23: NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008 - 2011
- Figure 1: NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008 -
AUGUST 2011
- Table 24: NEW DRUG APPLICATIONS, 2008 - AUGUST 2011
- Table 25: RECALLS, 2008 - AUGUST 2011
Chapter - 6: PREVALENCE
- U.S.
- EUROPE
- REST OF THE WORLD
- PREVALENCE OF CERTAIN TYPES OF LIVER DISEASE
Chapter - 7: INDUSTRY STRUCTURE
- MARKET SHARES OF INDUSTRY LEADERS FOR DRUGS USED TO TREAT LIVER DISEASE
- CHEMOTHERAPY
- Table 35: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
CHEMOTHERAPEUTIC AGENTS FOR LIVER CANCER AND TUMORS, 2010
- Figure 7: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
CHEMOTHERAPEUTIC AGENTS FOR LIVER CANCER AND TUMORS, 2010
Chapter - 8: NEW DEVELOPMENTS
- CLINICAL TRIALS
- LATEST RESEARCH ON LIVER DISEASE TREATMENT
Chapter - 9: MARKET ANALYSIS BY DRUG TYPES
- MARKET REVENUE
- MARKET SHARE
- VACCINES
- ANTIVIRALS
- IMMUNE GLOBULINS
- CHEMOTHERAPY
- TARGETED THERAPY
- DRUGS USED TO TREAT WILSON'S DISEASE: MINERALS AND CHELATING AGENTS
- CORTICOSTEROIDS
- IMMUNOSUPPRESSIVE AGENTS
- ANTIMETABOLITES
- ANABOLIC STEROIDS
- ALCOHOL-ABUSE DRUGS
- ANTI-REJECTION DRUGS
- INFECTION-FIGHTING DRUGS
- ANTIFUNGAL PROPHYLAXIS
- GALLSTONE-SOLUBILIZING AGENTS
- OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE
- MARKET SHARES FOR DRUG CATEGORIES USED TO TREAT LIVER DISEASES BY REGION
- Table 75: GLOBAL MARKET SHARES FOR DRUGS USED TO TREAT LIVER DISEASES BY
REGION, 2010
- Figure 41: GLOBAL MARKET SHARES FOR DRUGS USED TO TREAT LIVER DISEASES
BY REGION, 2010
Chapter - 10: MARKET BY DISEASE TYPE
- HEPATITIS
- LIVER TUMORS
- AUTOIMMUNE DISEASES
- ALCOHOL-INDUCED LIVER DISEASE
- CHRONIC LIVER DISEASE
- NON-ALCOHOLIC FATTY LIVER DISEASE
- MARKET SHARE BY DISEASE TYPE
- Table 89: DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, 2010
- Figure 55: DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, 2010
Chapter - 11: DRUG-INDUCED LIVER DISEASE
- DRUG-INDUCED LIVER DISEASE
- DRUGS THAT CAN CAUSE LIVER DISEASEDRUGS THAT CAN CAUSE LIVER DISEASE
Chapter - 12: PATENT ANALYSIS
- PATENTS BY YEAR
- PATENTS BY TYPE
- PATENTS BY COMPANY
- PATENTS BY COUNTRY
- PATENTS BY ASSIGNEE
- Table 95: PATENTS FOR DRUGS USED IN THE TREATMENT OF LIVER DISEASES BY
ASSIGNEE, 2009 - 2011
- Figure 61: PATENTS FOR DRUGS USED IN THE TREATMENT OF LIVER DISEASES BY
ASSIGNEE, 2009 - 2011
Chapter - 13: CURRENT SITUATION AND FUTURE PROSPECTS
- PREVALENCE AND LIFE EXPECTANCY
- LACK OF EDUCATION AND LIMITED TREATMENT OPTIONS
- RESEARCH AND DEVELOPMENT
- LIVER ORGANIZATIONS
Chapter - 14: COMPANY PROFILES
- ABBOTT LABORATORIES
- ACTAVIS INC.
- ALKERMES
- ASTELLAS PHARMA INC.
- ATON PHARMA (VALEANT PHARMACEUTICALS INTERNATIONAL)
- BARR
- BAYER SCHERING AG
- BIOTEST
- BRISTOL-MYERS SQUIBB
- CANGENE CORPORATION
- ELI LILLY
- FOREST LABORATORIES, INC.
- GILEAD SCIENCES, INC.
- GLAXOSMITHKLINE PLC
- IDENIX PHARMACEUTICALS, INC.
- MALLINCKRODT
- MEDA PHARMACEUTICALS
- MERCK & CO.
- MYLAN
- NOVARTIS
- PFIZER
- PROMETHEUS LABS
- ROCHE
- ROXANE LABORATORIES
- SALIX PHARMACEUTICALS
- SANOFI-AVENTIS
- SAVIENT PHARMACEUTICALS, INC.
- SCHERING PLOUGH CORPORATION
- TAKEDA PHARMACEUTICAL
- TALECRIS BIOTHERAPEUTICS
- THREE RIVERS PHARMACEUTICALS
- VALEANT PHARMACEUTICALS INTERNATIONAL
- VERTEX PHARMACEUTICALS, INC.
- WATSON PHARMACEUTICALS, INC.
- ZYDUS PHARMACEUTICALS INC.
Chapter - 15: APPENDIX: ABBREVIATIONS AND DEFINITIONS
List of Tables
- Summary Table: GLOBAL REVENUE FOR DRUGS USED TO TREAT LIVER DISEASES BY
REGION, THROUGH 2016
- Table 1: CLASSIFICATION OF LIVER DISEASE
- Table 2: VACCINES FOR HEPATITIS A PREVENTION
- Table 3: VACCINES FOR HEPATITIS B PREVENTION
- Table 4: NUCLEOSIDE ANALOGS USED TO TREAT HEPATITIS
- Table 5: NUCLEOTIDE ANALOGS USED TO TREAT HEPATITIS
- Table 6: INTERFERONS USED TO TREAT HEPATITIS
- Table 7: PROTEASE INHIBITORS USED TO TREAT HEPATITIS
- Table 8: IMMUNE GLOBULINS USED TO TREAT HEPATITIS
- Table 9: CHEMOTHERAPEUTIC DRUGS USED TO TREAT LIVER CANCER
- Table 10: TARGETED THERAPY USED TO TREAT LIVER CANCER
- Table 11: DRUGS USED TO TREAT WILSON'S DISEASE
- Table 12: CORTICOSTEROIDS USED TO TREAT AUTOIMMUNE HEPATITIS
- Table 13: IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITIS
- Table 14: ANTI-METABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS
- Table 15: ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DAMAGE
- Table 16: ALCOHOL-ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DAMAGE
- Table 17: ANTI-REJECTION MEDICATIONS
- Table 18: ANTI-INFECTIVES
- Table 19: ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS
- Table 20: GALLSTONE-SOLUBILIZING AGENTS USED TO TREAT NON-ALCOHOLIC FATTY
LIVER DISEASE
- Table 21: OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE
- Table 22: NEW DRUG APPROVALS, 2008 - AUGUST 2011
- Table 23: NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008 - 2011
- Table 24: NEW DRUG APPLICATIONS, 2008 - AUGUST 2011
- Table 25: RECALLS, 2008 - AUGUST 2011
- Table 26: U.S. PREVALENCE OF LIVER DISEASE
- Table 27: U.S. ANNUAL HEPATITIS PREVALENCE
- Table 28: U.S. HEPATITIS BURDEN, 2007 AND 2008
- Table 29: U.S. INCIDENCE OF ACUTE HEPATITIS BY SEX AND AGE, 2006
- Table 30: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF VACCINES
FOR HEPATITIS, 2010
- Table 31: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
NUCLEOSIDE ANALOGUES FOR HEPATITIS, 2010
- Table 32: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
NUCLEOTIDE ANALOGUES FOR HEPATITIS, 2010
- Table 33: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
INTERFERONS FOR HEPATITIS, 2010
- Table 34: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
IMMUNOGLOBULINS FOR HEPATITIS, 2010
- Table 35: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
CHEMOTHERAPEUTIC AGENTS FOR LIVER CANCER AND TUMORS, 2010
- Table 36: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF TARGETED
THERAPY AGENTS FOR LIVER CANCER AND TUMORS, 2010
- Table 37: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF MINERALS
AND CHELATING AGENTS TO TREAT WILSON'S DISEASE, 2010
- Table 38: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
CARTICOSTEROIDS FOR TREATING LIVER DISEASE, 2010
- Table 39: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
IMMUNOSUPPRESSIVE AGENTS FOR TREATING LIVER DISEASE, 2010
- Table 40: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
ANTIMETABOLITES FOR TREATING LIVER DISEASE, 2010
- Table 41: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF ANABOLIC
STEROIDS FOR TREATING LIVER DISEASE, 2010
- Table 42: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
ALCOHOL-ABUSE DRUGS, 2010
- Table 43: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
ANTI-REJECTION DRUGS, 2010
- Table 44: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
INFECTION-FIGHTING DRUGS USED AFTER LIVER TRANSPLANT, 2010
- Table 45: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
ANTIFUNGAL PROPHYLAXIS FOR TREATING LIVER TRANSPLANTS, 2010
- Table 46: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
GALLSTONE-SOLUBILIZING AGENTS, 2010
- Table 47: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF OTHER
DRUGS FOR NON-ALCOHOLIC FATTY LIVER DISEASE, 2010
- Table 48: CLINICAL TRIALS FOR HEPATITIS, 2009 - SEPTEMBER 2011
- Table 49: CLINICAL TRIALS FOR LIVER TUMORS, 2009 - SEPTEMBER 2011
- Table 50: CLINICAL TRIALS FOR AUTOIMMUNE LIVER DISORDERS, 2009 - SEPTEMBER
2011
- Table 51: CLINICAL TRIALS FOR ALCOHOL-INDUCED LIVER DISEASES, 2009 -
SEPTEMBER 2011
- Table 52: CLINICAL TRIALS FOR CHRONIC LIVER DISEASES, 2009 - SEPTEMBER 2011
- Table 53: CLINICAL TRIALS FOR NON-ALCOHOLIC FATTY LIVER DISEASE, 2009 -
SEPTEMBER 2011
- Table 54: GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER DISEASE, THROUGH 2016
- Table 55: DRUGS USED TO TREAT LIVER DISEASES, 2010
- Table 56: GLOBAL MARKET FOR VACCINES TO TREAT HEPATITIS BY REGION, THROUGH
2016
- Table 57: GLOBAL MARKET FOR NUCLEOSIDES TO TREAT HEPATITIS BY REGION,
THROUGH 2016
- Table 58: GLOBAL MARKET FOR NUCLEOTIDES TO TREAT HEPATITIS BY REGION,
THROUGH 2016
- Table 59: GLOBAL MARKET FOR INTERFERONS TO TREAT HEPATITIS BY REGION,
THROUGH 2016
- Table 60: GLOBAL MARKET FOR PROTEASE INHIBITORS TO TREAT HEPATITIS BY
REGION, THROUGH 2016
- Table 61: GLOBAL MARKET FOR IMMUNE GLOBULINS TO TREAT HEPATITIS BY REGION,
THROUGH 2016
- Table 62: GLOBAL MARKET FOR CHEMOTHERAPY DRUGS USED TO TREAT LIVER CANCER
AND TUMORS BY REGION, THROUGH 2016
- Table 63: GLOBAL MARKET FOR TARGETED THERAPY TO TREAT LIVER CANCER AND
TUMORS BY REGION, THROUGH 2016
- Table 64: GLOBAL MARKET FOR MINERALS AND CHELATING AGENTS TO TREAT
WILSON'S DISEASE BY REGION, THROUGH 2016
- Table 65: GLOBAL MARKET FOR CORTICOSTEROIDS TO TREAT LIVER DISEASE BY
REGION, THROUGH 2016
- Table 66: GLOBAL MARKET FOR IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER
DISEASE BY REGION, THROUGH 2016
- Table 67: GLOBAL MARKET FOR ANTIMETABOLITES TO TREAT LIVER DISEASE BY
REGION, THROUGH 2016
- Table 68: GLOBAL MARKET FOR ANABOLIC STEROIDS TO TREAT LIVER DISEASE BY
REGION, THROUGH 2016
- Table 69: GLOBAL MARKET FOR ALCOHOL-ABUSE DRUGS BY REGION, THROUGH 2016
- Table 70: GLOBAL MARKET FOR ANTI-REJECTION DRUGS FOR LIVER TRANSPLANTS BY
REGION, THROUGH 2016
- Table 71: GLOBAL MARKET FOR INFECTION-FIGHTING DRUGS FOR LIVER TRANSPLANTS
BY REGION, THROUGH 2016
- Table 72: GLOBAL MARKET FOR ANTIFUNGAL PROPHYLAXIS FOR LIVER DISEASES BY
REGION, THROUGH 2016
- Table 73: GLOBAL MARKET FOR GALLSTONE-SOLUBILIZING AGENTS BY REGION,
THROUGH 2016
- Table 74: GLOBAL MARKET FOR OTHER DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER
DISEASE BY REGION, THROUGH 2016
- Table 75: GLOBAL MARKET SHARES FOR DRUGS USED TO TREAT LIVER DISEASES BY
REGION, 2010
- Table 76: GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE
TYPE, THROUGH 2016
- Table 77: GLOBAL MARKET FOR DRUGS USED TO TREAT HEPATITIS, THROUGH 2016
- Table 78: GLOBAL SHARE FOR DRUGS USED TO TREAT HEPATITIS BY REGION, 2010
- Table 79: GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY
REGION, THROUGH 2016
- Table 80: GLOBAL SHARE FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY
REGION, 2010
- Table 81: GLOBAL MARKET FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES
BY REGION, THROUGH 2016
- Table 82: GLOBAL SHARE FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES
BY REGION, 2010
- Table 83: GLOBAL MARKET FOR DRUGS USED TO TREAT ALCOHOL-INDUCED LIVER
DISEASES BY REGION, THROUGH 2016
- Table 84: GLOBAL SHARE OF ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2010
- Table 85: GLOBAL MARKET FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY
REGION, THROUGH 2016
- Table 86: GLOBAL SHARE FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY
REGION, 2010
- Table 87: GLOBAL MARKET FOR DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER
DISEASE BY REGION, THROUGH 2016
- Table 88: GLOBAL SHARE FOR DRUGS USED TO TREAT NON ALCOHOLIC FATTY LIVER
DISEASE BY REGION, 2010
- Table 89: DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, 2010
- Table 90: DRUGS THAT CAN CAUSE LIVER DISEASE
- Table 91: PATENTS, 2009 - SEPTEMBER 2011
- Table 92: PATENTS BY TYPE, 2009 - SEPTEMBER 2011
- Table 93: U.S. PATENTS FOR DRUGS USED TO TREAT LIVER DISEASE BY COMPANY,
2009 - SEPTEMBER 2011
- Table 94: U.S. PATENTS BY COUNTRY, 2009 - SEPTEMBER 2011
- Table 95: PATENTS FOR DRUGS USED IN THE TREATMENT OF LIVER DISEASES BY
ASSIGNEE, 2009 - 2011
List of Figures
- Summary Figure: GLOBAL REVENUE FOR DRUGS USED TO TREAT LIVER DISEASES BY
REGION, 2009-2016
- Figure 1: NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008 -
AUGUST 2011
- Figure 2: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF VACCINES
FOR HEPATITIS, 2010
- Figure 3: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
NUCLEOSIDE ANALOGUES FOR HEPATITIS, 2010
- Figure 4: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
NUCLEOTIDE ANALOGUES FOR HEPATITIS, 2010
- Figure 5: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
INTERFERONS FOR HEPATITIS, 2010
- Figure 6: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF IMMUNE
GLOBULINS FOR HEPATITIS, 2010
- Figure 7: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
CHEMOTHERAPEUTIC AGENTS FOR LIVER CANCER AND TUMORS, 2010
- Figure 8: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF TARGETED
THERAPY AGENTS FOR LIVER CANCER AND TUMORS, 2010
- Figure 9: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF MINERALS
AND CHELATING AGENTS TO TREAT WILSON'S DISEASE, 2010
- Figure 10: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
CORTICOSTEROIDS FOR TREATING LIVER DISEASE, 2010
- Figure 11: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
IMMUNOSUPPRESSIVE AGENTS FOR TREATING LIVER DISEASE, 2010
- Figure 12: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
ANTIMETABOLITES FOR TREATING LIVER DISEASE, 2010
- Figure 13: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
ANABOLIC STEROIDS FOR TREATING LIVER DISEASE, 2010
- Figure 14: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
ALCOHOL-ABUSE DRUGS, 2010
- Figure 15: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
ANTI-REJECTION DRUGS, 2010
- Figure 16: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
INFECTION-FIGHTING DRUGS USED AFTER LIVER TRANSPLANT, 2010
- Figure 17: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
ANTIFUNGAL PROPHYLAXIS FOR TREATING LIVER TRANSPLANTS, 2010
- Figure 18: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF
GALLSTONE-SOLUBILIZING AGENTS, 2010
- Figure 19: GLOBAL MARKET SHARES FOR MANUFACTURERS AND SUPPLIERS OF OTHER
DRUGS FOR NON-ALCOHOLIC FATTY LIVER DISEASE, 2010
- Figure 20: GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER DISEASE, 2009-2016
- Figure 21: DRUGS USED TO TREAT LIVER DISEASES, 2010
- Figure 22: GLOBAL MARKET FOR VACCINES TO TREAT HEPATITIS BY REGION,
2009-2016
- Figure 23: GLOBAL MARKET FOR NUCLEOSIDES TO TREAT HEPATITIS BY REGION,
THROUGH 2016
- Figure 24: GLOBAL MARKET FOR NUCLEOTIDES TO TREAT HEPATITIS BY REGION,
2009-2016
- Figure 25: GLOBAL MARKET FOR INTERFERONS TO TREAT HEPATITIS BY REGION,
2009-2016
- Figure 26: GLOBAL MARKET FOR PROTEASE INHIBITORS TO TREAT HEPATITIS BY
REGION, 2009-2016
- Figure 27: GLOBAL MARKET FOR IMMUNE GLOBULINS TO TREAT HEPATITIS BY
REGION, 2009-2016
- Figure 28: GLOBAL MARKET FOR CHEMOTHERAPY DRUGS USED TO TREAT LIVER CANCER
AND TUMORS BY REGION, 2009-2016
- Figure 29: GLOBAL MARKET FOR TARGETED THERAPY TO TREAT LIVER CANCER AND
TUMORS BY REGION, 2009-2016
- Figure 30: GLOBAL MARKET FOR MINERALS AND CHELATING AGENTS TO TREAT
WILSON'S DISEASE BY REGION, 2009-2016
- Figure 31: GLOBAL MARKET FOR CORTICOSTEROIDS TO TREAT LIVER DISEASE BY
REGION, 2009-2016
- Figure 32: GLOBAL MARKET FOR IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER
DISEASE BY REGION, 2009-2016
- Figure 33: GLOBAL MARKET FOR ANTIMETABOLITES TO TREAT LIVER DISEASE BY
REGION, 2009-2016
- Figure 34: GLOBAL MARKET FOR ANABOLIC STEROIDS TO TREAT LIVER DISEASE BY
REGION, 2009-2016
- Figure 35: GLOBAL MARKET FOR ALCOHOL-ABUSE DRUGS BY REGION, 2009-2016
- Figure 36: GLOBAL MARKET FOR ANTI-REJECTION DRUGS FOR LIVER TRANSPLANTS BY
REGION, 2009-2016
- Figure 37: GLOBAL MARKET FOR INFECTION-FIGHTING DRUGS FOR LIVER
TRANSPLANTS BY REGION, 2009-2016
- Figure 38: GLOBAL MARKET FOR ANTIFUNGAL PROPHYLAXIS FOR LIVER DISEASES BY
REGION, 2009-2016
- Figure 39: GLOBAL MARKET FOR GALLSTONE-SOLUBILIZING AGENTS BY REGION,
2009-2016
- Figure 40: GLOBAL MARKET FOR OTHER DRUGS TO TREAT NON-ALCOHOLIC FATTY
LIVER DISEASE BY REGION, 2009-2016
- Figure 41: GLOBAL MARKET SHARES FOR DRUGS USED TO TREAT LIVER DISEASES BY
REGION, 2010
- Figure 42: GLOBAL MARKET FOR DRUG USED TO TREAT LIVER DISORDERS BY DISEASE
TYPE, 2009-2016
- Figure 43: GLOBAL MARKET FOR DRUGS USED TO TREAT HEPATITIS, 2009-2016
- Figure 44: GLOBAL SHARE FOR DRUGS USED TO TREAT HEPATITIS BY REGION, 2010
- Figure 45: GLOBAL MARKET FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER
BY REGION, 2009-2016
- Figure 46: GLOBAL SHARE FOR DRUGS USED TO TREAT LIVER TUMORS AND CANCER BY
REGION, 2010
- Figure 47: GLOBAL MARKET FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES
BY REGION, 2009-2016
- Figure 48: GLOBAL SHARE FOR DRUGS USED TO TREAT AUTOIMMUNE LIVER DISEASES
BY REGION, 2010
- Figure 49: GLOBAL MARKET FOR DRUGS USED TO TREAT ALCOHOL-INDUCED LIVER
DISEASES BY REGION, 2009-2016
- Figure 50: GLOBAL SHARE OF ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2010
- Figure 51: GLOBAL MARKET FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY
REGION, 2009-2016
- Figure 52: GLOBAL SHARE FOR DRUGS USED TO TREAT CHRONIC LIVER DISEASES BY
REGION, 2010
- Figure 53: GLOBAL MARKET FOR DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER
DISEASE BY REGION, 2009-2016
- Figure 54: GLOBAL SHARE FOR DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER
DISEASE BY REGION, 2010
- Figure 55: DRUGS USED TO TREAT LIVER DISORDERS BY DISEASE TYPE, 2010
- Figure 56: PATENTS, 2009 - SEPTEMBER 2011
- Figure 57: PATENTS, 2009 - SEPTEMBER 2011
- Figure 58: PATENTS BY TYPE, 2009 - SEPTEMBER 2011
- Figure 59: U.S. PATENTS FOR DRUGS USED TO TREAT LIVER DISEASE BY COMPANY,
2009 - SEPTEMBER 2011
- Figure 60: U.S. PATENTS BY COUNTRY, 2009 - SEPTEMBER 2011
- Figure 61: PATENTS FOR DRUGS USED IN THE TREATMENT OF LIVER DISEASES BY
ASSIGNEE, 2009 - 2011
預計2016年全球肝臟疾病治療藥市場將超過141億美元
2012年02月13日
Global Information, Inc.已開始銷售BCC Research所發行的報告書「Liver Disease Treatments: The Global Market (全球的肝臟疾病治療藥市場)」
2011年肝臟疾病治療藥的收益達到120億美元。該市場今後將以複合年成長率(CAGR)3.3％推移，2016年預計達到142億美元左右。
肝臟疾病治療藥市場可分成美國、歐洲與其他3個地區。
2011年美國地區是42億美元市場規模，預計之後以CAGR 3％成長，2016年時超過49億美元。
2011年歐洲地區是約36億美元規模，預計之後以CAGR 1％推移，2016年時超過37億美元。
2011年全球其他地區42億美元規模，預測之後以CAGR 5.4％成長，2016年時達到55億美元左右。
肝臟疾病是美國罹病率高的疾病之一，且是所有年齡層都會罹患的疾病，然最容易罹患者是40歲到60歲之間。
近25年肝臟疾病的醫療研究，大幅改善患者的生存率和生活品質。然為能控制肝臟疾病影響人類健康和幸福，研究須更加進步。
現在有許多產品處於各種開發階段，治療肝臟疾病的物理治療有帶來大幅變化的可能性。
|
